The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the Committee for Medicinal Products for Human Use - Tzogani, Kyriaki; Mickisch, Gerald (The oncologist, 2015)
Gesehen am 27.11.2018